In September 2022, the FDA has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. 89% achieved transfusion independence with Hb > 8 g/dL. Common side effects: mommy comities, neutropenia, thrombocytopenia, anemia.
Studying for im boards! Thanks for the refresher.
In September 2022, the FDA has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. 89% achieved transfusion independence with Hb > 8 g/dL.
Common side effects: mommy comities, neutropenia, thrombocytopenia, anemia.
Thanks do much Dr for thy strives to make everything clear
Thank you for this concise presentation
What a great video! A wonderful explanation for a complicated topic. I found this to be extremely helpful while studying for my board exam. Thanks!!
1ùķo
Great Lectures ❤
Glad you like them!
Wonderful explanation sir
I'm an indian
Thank you for the brief video!
You’re welcome!
Doctor can you explain how to diagnose cases according to CBC and HLPC